echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > ChK1 inhibitors! Bibert Pharmaceuticals Class 1 new drugs were approved clinically.

    ChK1 inhibitors! Bibert Pharmaceuticals Class 1 new drugs were approved clinically.

    • Last Update: 2020-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to information made public by the Drug Review Center (CDE) of the State Drug Administration of China, BEBT-260, a new class of chK1 inhibitors injected by Bibert Pharmaceuticals, has obtained an implied license for clinical trials to treat advanced solid tumors that recur after at least two systemic treatments.
    note that no ChK1 inhibitors have yet been approved for the global market.
    BEBT-260 is a selective and powerful cell cycle ChK1 inhibitor with an innovative chemical structure and global ownership of Bibert Pharmaceuticals.
    cell cycle checkpoint kinase 1 (ChK1, checkpoint kinase 1) is a member of the serine/suline protein kinase family and is the core protein of the cell cycle detection point in the DNA damage response (DNA damage response, DDR).
    studies have shown that Chk1 protein kinase has the function of promoting tumor cell growth, its lack of tumor cells can be more sensitive to radiotherapy or chemotherapy, and its inhibitors in combination with other molecularly targeted drugs have a "synthetic lethal" effect.
    chk1 is also seen as one of the targets of cancer treatment.
    , BEBT-260 enhances the activity of chemotherapy drugs in a variety of tumor cells.
    beBT-260 showed significant anti-tumor activity when used alone or in combination with chemotherapy drugs.
    , Bibert Pharmaceuticals intends to use the product alone or in combination with chemotherapy drugs for the treatment of various solid tumors, especially 2003-carrying TP53 mutations.
    , chK1 inhibitors have not yet been approved for the global market.
    are also less clinically developing ChK1 inhibitors, which are known to be being developed by companies such as Lilly, Roche and Sierra Oncology.
    congratulations on the approval of Bibbett Pharmaceuticals BEBT-260 clinically, and looks forward to the smooth progress of the follow-up research of this product to bring innovative therapies to patients at an early time.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.